SRNE News and Press, Sorrento Therapeutics Inc. From 11/09/22

Summary Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business. Management compensation is very high. Sorrento Therapeutics ( SRNE ) is a commercial-stage company that, I would say, made a more o...

Summary While its CEO bruits a future market cap of hundreds of billions, Sorrento's current cap is angling down to <$0.7 billion. Sorrento has a diverse pipeline centered on oncology, infectious disease and non-opioid pain relief. Sorrento's latest proxy reveals ongoing ou...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful. However, everyone must realize that...

SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closin...

Sorrento Therapeutics (SRNE stock) ( NASDAQ:SRNE ) looks to be a major benefactor of this rising tide phenomenon. The drugmaker’s stock is rising today, mirroring the larger biopharmaceutical sector. What Happened to SRNE stock? Today, SRNE stock ( NAS...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Contrarian investing is not easy, and it certainly takes a great deal of courage. Forbes defines contrarian investing as “holding a viewpoint on the market that is out of favor, and then doing the necessary ...

Shares of the diversified biopharma Sorrento Therapeutics (NASDAQ: SRNE) are racing higher today. Specifically, the drugmaker's shares are up by a healthy 5% on moderate volume as of 11:23 a.m. ET on Thursday. What's propelling Sorrento's stock northward today? Its shares appear...

Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg and 2,000 mg doses in the single ascending dose (SAD) portion of the study and 300 mg, 600 mg and 800 mg BID (twice a day) daily for 7.5 days in the multiple ascending dose (MAD...

SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity agains...

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader (KOL) Panel Discussion that will focus on the great unmet need ...